Therefore, blocking EGFR activation in astrocytes could be beneficial for the treatment of neuroinflammation, which characterizes CNS neurodegenerative diseases including Alzheimer’s disease although this has still to be proved. This evidence concerns the gene EGFR and early-onset autosomal dominant Alzheimer disease.